This week's Infectious Disease digest · 2026-W24
This Week in Infectious Disease: PrEP Awareness and Antibiotic Efficacy
C-reactive protein testing impacts antibiotic prescribing rates in acute COPD exacerbations
Blood tests may help doctors decide when to use antibiotics
Integrating C-reactive protein tests into primary care may significantly reduce unnecessary antibiotic prescriptions for patients with acute…
A new look at blood tests suggests a specific test can help doctors decide if patients with lung disease truly need antibiotics.
FDA Approves Veklury (remdesivir) for COVID-19 in Adults and Pediatric Patients
FDA approves Veklury to treat COVID-19 in adults and children.
The FDA approved Veklury (remdesivir) for the treatment of COVID-19 in adults and pediatric patients (birth to less than 18 years weighing a…
The FDA approved Veklury (remdesivir) for treating COVID-19 in adults and children who are hospitalized or at high risk of severe disease. T…
Skin colonization by Candida auris is a key factor in high transmissibility and outbreak potential
Skin Colonization Key to Candida auris Spread
This systematic review examines the epidemiological characteristics, microbiota alterations, and decolonization strategies for Candida auris…
Candida auris spreads easily because it colonizes skin. New review explains why and what to do.
Hydrogen sulfide mediates bacterial antibiotic tolerance through iron chelation, efflux pump activation, and metabolic dormancy
Hydrogen Sulfide May Help Overcome Bacterial Antibiotic Tolerance
This systematic review synthesizes the role of hydrogen sulfide (H2S) in mediating multidrug tolerance in bacteria. The authors identify thr…
New research identifies how hydrogen sulfide helps bacteria resist antibiotics, offering a potential new way to target and eliminate persist…
FDA Approves Dyna-hex 4 (chlorhexidine gluconate) for Healthcare Personnel Handwash
FDA approves Dyna-hex 4 for handwashing and skin cleansing.
The FDA approved Dyna-hex 4 (chlorhexidine gluconate) for healthcare personnel handwash, skin wound cleansing, and general skin cleansing. T…
The FDA approved Dyna-hex 4 (chlorhexidine gluconate) for use as a handwash and skin cleanser in healthcare settings. It helps reduce bacter…
FDA Approves Kaletra (lopinavir/ritonavir) for HIV-1 Infection in Adults and Children
FDA approves new HIV drug Kaletra for adults and children.
FDA approved Kaletra (lopinavir/ritonavir) for treatment of HIV-1 infection in adults and pediatric patients 14 days and older, in combinati…
The FDA approved Kaletra (lopinavir/ritonavir) to treat HIV-1 infection in adults and children aged 14 days and older. It is used with other…
FDA Approves Kaletra (lopinavir/ritonavir) for HIV-1 Infection in Patients 14 Days and Older
FDA approves Kaletra to treat HIV in adults and children 14 days and older.
The FDA approved Kaletra (lopinavir/ritonavir) for HIV-1 infection in adults and pediatric patients 14 days and older, in combination with o…
The FDA approved Kaletra (lopinavir/ritonavir) for HIV-1 infection in adults and children as young as 14 days. It is used with other HIV med…
FDA Approves Dyna-hex 2 (chlorhexidine gluconate) for Surgical Hand Scrub and Healthcare Personnel Handwash
FDA approves Dyna-hex 2 antiseptic for surgical hand scrubs and healthcare handwash.
The FDA approved Dyna-hex 2 (chlorhexidine gluconate) for use as a surgical hand scrub and healthcare personnel handwash. It significantly r…
The FDA approved Dyna-hex 2 (chlorhexidine gluconate) as a surgical hand scrub and healthcare handwash to reduce bacteria on hands and forea…
Bacteriophages show promise as targeted anti-caries agents in systematic review
Bacteriophages Show Promise Against Cavities
This systematic review summarizes advances in phage-based interventions for dental caries, including phages targeting S. mutans and Actinomy…
Viruses that target bacteria could one day help prevent and treat cavities by killing cavity-causing germs.
Protocol for comparing azithromycin and doxycycline with beta-lactams in community-acquired pneumonia
New trial to test azithromycin vs doxycycline for pneumonia
This is a protocol for a planned randomized clinical trial involving 1120 adult patients hospitalized with community-acquired pneumonia. No …
A large trial will compare two antibiotic combos for hospitalized pneumonia patients. Which works better?
Digital PCR provides a strong correlation with plaque assays for disinfectant efficacy testing
Digital PCR Shows Strong Correlation with Traditional Disinfectant Testing
This guideline-based validation study evaluates digital PCR (dPCR) as a complement to MS2 plaque assays for assessing virucidal activity. Th…
A new laboratory test shows that digital PCR can accurately track how well disinfectants kill viruses compared to traditional methods.
PPI deprescription associated with 3.66 odds of CDI in hospitalized older adults
Stopping certain acid medications might increase risk of stomach infection
This quasi-interventional substudy of a cluster randomized trial involved 4990 hospitalized older adults taking five or more medications. Th…
A study of nearly 5,000 hospitalized seniors found that stopping specific acid-reducing drugs could actually lead to more frequent infection…
All Infectious Disease Articles
- C-reactive protein testing impacts antibiotic prescribing rates in acute COPD exacerbations
- FDA Approves Veklury (remdesivir) for COVID-19 in Adults and Pediatric Patients
- Skin colonization by Candida auris is a key factor in high transmissibility and outbreak potential
- Hydrogen sulfide mediates bacterial antibiotic tolerance through iron chelation, efflux pump activation, and metabolic dormancy
- FDA Approves Dyna-hex 4 (chlorhexidine gluconate) for Healthcare Personnel Handwash
- FDA Approves Kaletra (lopinavir/ritonavir) for HIV-1 Infection in Adults and Children
- FDA Approves Kaletra (lopinavir/ritonavir) for HIV-1 Infection in Patients 14 Days and Older
- FDA Approves Dyna-hex 2 (chlorhexidine gluconate) for Surgical Hand Scrub and Healthcare Personnel Handwash
- Digital PCR provides a strong correlation with plaque assays for disinfectant efficacy testing
- Protocol for comparing azithromycin and doxycycline with beta-lactams in community-acquired pneumonia
- Bacteriophages show promise as targeted anti-caries agents in systematic review
- PPI deprescription associated with 3.66 odds of CDI in hospitalized older adults
- Antimicrobial resistance drivers in human and agricultural sectors contribute to 4.95 million annual deaths
- Intravesical aminoglycoside instillations reduce recurrent urinary tract infection risk with an IRR of 0.23
- Comparing antimicrobial resistance to COVID-19 does not reduce antibiotic seeking intentions in US adults
- Voriconazole and surgical management successfully treated Aspergillus flavus infection in a patient with spondylolisthesis
- Ensitrelvir plus standard of care does not improve clinical recovery in hospitalized COVID-19 patients
- 4CMenB vaccine did not reduce infection rates compared to placebo in MSM population
- FDA Approves Augmentin XR (amoxicillin/clavulanate) for Community-Acquired Pneumonia and Acute Bacterial Sinusitis
- FDA Approves Augmentin (amoxicillin/clavulanate) for Bacterial Infections
- FDA Approves Augmentin (amoxicillin/clavulanate) for Bacterial Infections
- Chinese pediatric surgeons know prophylaxis guidelines but often fail to stop antibiotics at 24 hours
- Genome-predicted PBP profiling shows high agreement with phenotypic testing for pneumococcal beta-lactam susceptibility
- Nocardia keratitis virulence factors and host immune pathways mapped in systematic review
- HIV-related factors including antiretroviral therapy and low CD4+ counts associate with higher cardiovascular risk
- SP+AQ cuts malaria incidence 54.6% versus SP alone in African children
- Tablet-guided training improves HIV index case testing fidelity by 30.5 percentage points
- Bidirectional automated texting engages 60.3% of people living with HIV for cardiovascular health
- Dual-ART and triple-ART both reduce plasma biomarkers of immune activation and neuronal injury
- Dolutegravir and lamivudine achieved 78% HIV-1 RNA suppression in patients with isolated reactive anti-HBc
- Impact of Rapid Multiplex Point of Care Testing on Antibiotic Prescribing
- Fidaxomicin and vancomycin pulse and taper regimens show potential for reducing Clostridioides difficile recurrence
- Magnesium phosphate cements demonstrate superior biological interactions and faster resorption than calcium phosphate cements
- Targeted interventions increase condom use and HIV knowledge among long-distance truck drivers
- Multidrug-resistant tuberculosis prevalence is 5.2% among patients with bacteriologically confirmed cases in Cameroon
- Chlorhexidine reduces alveolar osteitis risk by 42.9% after third molar surgery
- Sotorasib resistance linked to transformation to pulmonary giant cell carcinoma in KRAS G12C lung adenocarcinoma
- Antimicrobial additives in resin-based endodontic sealers enhance antibacterial activity against Enterococcus faecalis
- Multimodal laboratory diagnostics improve detection of biofilm-encased pathogens and polymicrobial infections in bone and joint infections
- TCM-based extracts reduce pain in oral lichen planus by 0.86 points on VAS
- Image-guided RFA and MWA show comparable efficacy and safety for small to medium hepatocellular carcinoma
- NLRP3 inhibition and IL-1 receptor blockade attenuate musculoskeletal pathology in alphavirus infections
- Syphilis prevalence is 5.20-fold higher in low-income countries among forcibly displaced populations
- NSP antibody detection aids DIVA interpretation in foot-and-mouth disease but has key limits
- Brain-Lung-Immune-Microbiome Axis replaces biomechanical models in understanding ventilator-associated pneumonia after traumatic brain injury
- FDA Approves Zithromax (azithromycin) for Mild to Moderate Bacterial Infections
- FDA Approves Zithromax (azithromycin) for Mild to Moderate Bacterial Infections
- FDA Approves Zithromax (azithromycin) for Multiple Bacterial Infections
- FDA Approves Zithromax (azithromycin) for Community-Acquired Pneumonia and Pelvic Inflammatory Disease
- FDA Approves Sporanox (itraconazole) for Blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis
- FDA Approves Fetroja (cefiderocol) for Complicated UTIs and Hospital-Acquired Pneumonia
- 5-day oral antibiotics as effective as 10-day course for pediatric GAS pharyngitis
- Cefdinir and cefprozil show superior eradication rates compared to penicillin V for Group A streptococcal pharyngitis
- Vonoprazan-amoxicillin dual therapy is a safe alternative to bismuth-containing quadruple therapy for H. pylori
- Favipiravir co-administration with lopinavir-ritonavir increased favipiravir clearance by twofold in COVID-19 patients
- Evaluating Enhanced Intervention Strategies for Trachoma Elimination in Rural Ethiopian Communities
- Health insurance navigation after HIV testing was acceptable for 50.0% of eligible men
- Novel biomarkers and machine learning algorithms facilitate earlier identification and diagnosis of sepsis
- Three-variable stratification tool identifies risk of invasive pulmonary aspergillosis in SFTS patients
- 0.01% atropine reduces axial length by 0.04 mm/year in children with myopia
- Salmonella prevalence in bovine deep tissue lymph nodes reaches 10.8% across 33 studies
- NF-kB pathway serves as a unifying hub for molecular and clinical phenotypes in post-acute infection syndrome
- APOE ε4 status does not significantly impact neurocognitive performance in adults with HIV infection
- Triple antibiotic paste and calcium hydroxide show comparable success in necrotic immature teeth
- Doxycycline provides higher odds of microbiological cure compared to azithromycin in cis-men with chlamydia
- Antibiotic resistance mutations drive H. pylori treatment failure across Asia-Pacific region
- Colistin-based inhalation regimens rank highest for clinical response in multidrug-resistant Acinetobacter baumannii pneumonia
- Many healthcare students lack knowledge that antibiotics do not speed recovery from colds and flu
- Pooled Salmonella prevalence in Ethiopia is 6.7% with significant regional and source variations
- Long-acting injectable antiretroviral therapy shows equivalence to oral therapy in meta-analysis of 9 RCTs
- Cefmetazole or flomoxef linked to higher 14-day mortality vs carbapenems in ESBL-PE bacteremia
- Non-invasive biomarkers offer potential alternatives to invasive kidney biopsy for monitoring renal allograft pathology
- FDA Approves Bicillin C-R (penicillin G benzathine and procaine) for Streptococcal and Pneumococcal Infections
- FDA Approves Bicillin L-A (penicillin G benzathine) for Streptococcal Infections and Syphilis
- FDA Approves Arikayce (amikacin liposome inhalation suspension) for Refractory MAC Lung Disease
- FDA Approves Zevtera (ceftobiprole) for Staphylococcus aureus Bloodstream Infections, ABSSSI, and CABP
- Intralesional human papillomavirus vaccination significantly increases complete clearance of persistent cutaneous warts
- Ensitrelvir improves viral clearance and reduces viral RNA in patients with mild-to-moderate COVID-19
- HBeAg seroclearance in HBeAg-positive chronic hepatitis B correlates with disease remission and reduced hepatocellular carcinoma risk
- Klebsiella pneumoniae shows 44% pooled prevalence of antibiotic resistance in Burkina Faso healthcare settings
- 6-month bedaquiline, linezolid, delamanid, and levofloxacin or clofazimine regimen is noninferior to 9-month standard care
- Berberine reduces weight, lipids in schizophrenia with metabolic syndrome: meta-analysis
- Doravirine and islatravir combination shows reduced virological failure risk in adults with HIV-1
- Climate change drives increased frequency of vector-borne diseases through expansion of endemic areas
- Sugar acts as a pivotal ecological factor influencing metabolism, biofilm formation, and interspecies interactions in dental caries
- Computational strategies facilitate identification of conserved antigens and potential therapeutics in parasitic diseases
- Gram-negative organisms and multidrug resistance are prevalent in dental unit waterlines
- No risk score outperformed WHO IMCI criteria for predicting pediatric pneumonia mortality
- Mycobacteriophages show promise for drug-resistant mycobacterial infections in One Health approach
- FDA Approves Zyvox (linezolid) for Gram-Positive Infections Including MRSA
- FDA Approves Linezolid Injection for Gram-Positive Infections Including Pneumonia and Skin Infections
- Intrawound vancomycin powder reduces postoperative infection risk (OR 0.59) in high-risk fracture fixation cases
- Risk-adapted HLA delisting and imlifidase enable deceased-donor kidney transplantation for highly sensitized candidates
- Regenerative endodontic procedures may lead to unusual root morphology in immature teeth
- Plant essential oils demonstrate significant inhibitory effects against key subgingival plaque microbial complexes in periodontitis
- Fungal biotransformation platform may generate new anti-infective molecules to combat antimicrobial resistance
- Gay men show higher rates of PrEP awareness and use than bisexual men
- Conjugation governs the spread of resistance genes in bacterial populations across ecological compartments
- Early-life microbiome shapes allergic, metabolic, and respiratory disease risk
- Water buffalo act as reservoirs for infectious diseases in mixed livestock systems
- PEG-IFN plus novel agents may boost functional cure in chronic hepatitis B
- Antibiotic prophylaxis reduces UTI risk in children with VUR but increases antibiotic resistance
- Apodemus mice are key reservoirs for Borrelia and Neoehrlichia, but landscape drives tick-borne pathogen risk
- CDK4/6 inhibitors show therapeutic potential in advanced gastrointestinal cancers, review finds
- Standardized environmental AMR detection needed for regulatory interpretation and concern tiering
- HIV linked to lower odds of post-TB lung disease; undernutrition raises risk
- Microbial metabolites may promote or suppress cancer progression through inflammation, DNA damage, or immune modulation
- Inhaled antibiotics improve clinical cure and reduce mortality in ventilator-associated pneumonia
- Bictegravir/emtricitabine/tenofovir alafenamide shows favorable lipid and renal changes versus other regimens in treatment-experienced HIV-1 patients
- Bacteriophages modulate macrophage functions and immune responses in therapeutic applications
- Erratum notice published without clinical study data or findings
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum notice published without study details or clinical findings
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not provided
- Erratum published for unspecified study; clinical interpretation requires caution
- Correction notice issued for report on alcohol-related deaths and life years lost in US
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; clinical details not reported
- Erratum issued for COVID-19 hospitalization data among health care personnel
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; details and findings not reported
- Erratum issued for telehealth trends study during early COVID-19 pandemic
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; no clinical data available.
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified clinical study details
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; details on intervention and outcomes not reported
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; details on intervention and outcomes not reported
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; clinical details not available
- Erratum published for unspecified study; clinical details not available
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; no clinical data available.
- Erratum published for unspecified study; clinical evidence remains unclear
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; details on intervention and outcomes not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; details on intervention and outcomes not reported
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; no clinical data available for review.
- Erratum published for unspecified study; details on intervention and outcomes not reported
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; details and findings not reported
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical interpretation requires caution
- Erratum notice published for MMWR Vol. 71, No. 42; no study data available
- Erratum published for MMWR Vol. 69 SS-7, correcting a prior report.
- Erratum notice published for MMWR Vol. 70 SS-9 report
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; no clinical data available for review
- Erratum notice published without clinical findings or study data
- Erratum published for unspecified study; no clinical data available for review.
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not available
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical evidence remains unclear
- Erratum published for unspecified study; clinical details not available
- Retraction and republication notice issued for study on timing of complementary foods
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; no clinical data available for review
- Erratum published for unspecified study; clinical details not available
- Erratum published for unspecified study; clinical details not reported
- Erratum notice published without clinical data or study findings
- Erratum published for unspecified study; clinical details not reported
- Erratum published for unspecified study; clinical interpretation requires caution
- Erratum notice published without study data, methods, or findings
- Erratum published for unspecified study; clinical details not available